March 17, 2009

Rheonix Receives EPA Funding to Complete the Development of an Automatic Biosensor for Waterborne Pathogens

Ithaca, N.Y. — March 17, 2009 — Rheonix Inc., a privately-held biomedical device company known for its revolutionary, microfluidic, in vitro diagnostic platform, announced an additional $120,000 award from the U.S. Environmental Protection Agency (EPA) to further commercialize its biosensor technology for the rapid detection of Cryptosporidium parvum in drinking water. Cryptosporidium parvum can cause serious illness in infants and the elderly. The largest outbreak of the infection occurred in Milwaukee… Read More »
Rheonix receives FDA Emergency Use Authorization for Automated COVID-19 Test.
Learn More